Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2024

The following share repurchase programs have been authorized by the Board:


In billions Authorization Date	Authorized		Remaining as of December 31, 2024
November 17, 2022 (“2022 Repurchase Program”)	$	10.0	$	10.0
December 9, 2021 (“2021 Repurchase Program”)	10.0		1.5

Schedule of Regulatory Requirements

The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December 31, 2024, 2023 and 2022 for the Company’s insurance and HMO subsidiaries were as follows:


In millions	2024		2023		2022
Statutory net income (loss)	$	(1,185)	$	2,757	$	2,851
Estimated statutory capital and surplus	20,085		16,961		15,503

Statutory Accounting Practices Disclosure

At December 31, 2024, these amounts were as follows:


In millions
Estimated minimum statutory surplus required by regulators	$	11,691
Investments on deposit with regulatory bodies	713
Estimated maximum dividend distributions permitted in 2025 without prior regulatory approval	1,561

- Definition

Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.

+ References + Details